Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InVitria, a developer, manufacturer and marketer of a portfolio of cell culture media components and reagents used in biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics, has launched Zap-Hybridoma that provides a solution for hybridoma cell culture.
Subscribe to our email newsletter
Zap-Hybridoma was created to improve monoclonal antibody productivity and deliver easier purification of the target product. Zap-Hybridoma was developed by InVitria’s cell culture development team.
Steve Pettit, director of cell culture development at InVitria, said: “Not only can Zap-Hybridoma increase productivity, it delivers consistent results and allows hybridoma cells to more quickly adapt away from FBS (fetal bovine serum). We tested Zap-Hybridoma in six of the leading commercial hybridoma media on the market today and observed faster cell growth, a 50% average increase in maximum cell density and increased monoclonal antibody yield when compared to the recommended use of the manufacturer.”
Scott Deeter, president and CEO at InVitria, said: “Zap-Hybridoma is an innovation InVitria is proud to bring to its customers so they can achieve better performance more consistently. We developed Zap-Hybridoma to give users an IgG free alternative to FBS without sacrificing performance.”